磷酸丙吡胺片治疗室性心律失常的临床研究

Clinical trial of disopyramide phosphate tablets in the treatment of ventricular arrhythmia

目的观察磷酸丙吡胺片治疗室性心律失常的临床疗效及安全性。方法将60例室性心律失常患者随机分为对照组和试验组,每组30例。对照组予以阿替洛尔片每次50 mg,bid,口服;试验组予以磷酸丙吡胺片每次0.2 g,bid,口服。2组患者均治疗4周。比较2组患者的临床疗效、动态心电图指标、心功能,以及药物不良反应的发生情况。结果治疗后,试验组和对照组的总有效率分别为86.67%(26例/30例)和60.00%(18例/30例),差异有统计学意义(P<0.05)。治疗后,试验组和对照组的室性早搏分别为(2199.17±395.87)和(3815.52±637.15)次/天,阵发性室上性心动过速分别为(2.38±1.05)和(4.62±2.18)次/天,射血分数分别为(64.75±8.88)%和(53.18±9.10)%,差异均有统计学意义(均P<0.05)。试验组发生的药物不良反应以低血压、肠胃不适和失眠为主,对照组发生的药物不良反应以低血压和窦性心动过缓为主。试验组和对照组的总药物不良反应发生率分别为16.67%和10.00%,差异无统计学意义(P>0.05)。结论磷酸丙吡胺片治疗室性心律失常的临床疗效确切,其能有效改善患者的心功能,消除室性早搏,且不增加药物不良反应的发生率。

Objective To observe the clinical efficacy and safety of disopyramide phosphate tablets in treatment of ventricular arrhythmia.Methods A total of 60 patients with ventricular arrhythmia were randomly divided into control and treatment groups with 30 cases per group. Control group was given atenolol tablets 50 mg per time,bid,orally. Treatment group was given disopyramide phosphate tablets 0. 2 g per time,bid,orally. Two groups were treated for 4 weeks. The clinical efficacy,dynamic electrocardiogram index,cardiac function and adverse drug reactions were compared between two groups. Results After treatment,the total effective rates of treatment and control groups were86. 67%（ 26 cases/30 cases） and 60. 00%（ 18 cases/30 cases） with significant difference（ P〈0. 05）. After treatment,the main indexes in treatment and control groups were compared： the premature ventricular contractions were（ 2199. 17 ± 395. 87） and（ 3815. 52 ± 637. 15） beat·d^（-1）,paroxysmal supraventricular tachycardia were（ 2. 38 ± 1. 05） and（ 4. 62 ± 2. 18） beat · d^（-1）, left ventricular ejection fractions were（ 64. 75 ± 8. 88） % and（ 53. 18 ± 9. 10） %,the differences were statistically significant（ all P〈0. 05）. The adverse drug reactions of treatment group were low blood pressure,gastrointestinal distress and insomnia,which in control group were low blood pressure and sinus bradycardia. The total incidences of adverse reactions in treatment and control groups were 16. 67% and10. 00% without significant difference（ P〉0. 05）. Conclusion Disopyramide phosphate tablets have a definitive clinical efficacy in the treatment of ventricular arrhythmia,which can effectively improve patients＇ cardiac function,and eliminate premature ventricular contraction,without increasing the incidence of adverse drug reactions.